Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Sentinel Framework Should Preclude “Unbridled” Data Mining – Platt

Executive Summary

FDA's nascent electronic post-market drug safety monitoring project - Sentinel - should be designed to investigate only known problems or specific issues raised by spontaneous reports or studies, Harvard University's Richard Platt recommends
Advertisement

Related Content

Aetna Plans “Clinical Alert” On Plavix Use With PPIs Based On Claims Review
Aetna Plans “Clinical Alert” On Plavix Use With PPIs Based On Claims Review
E-Prescribing Incentives Offer Model For Electronic Records – CBO’s Orszag
E-Prescribing Incentives Offer Model For Electronic Records – CBO’s Orszag
FDA’s Sentinel Program Readies For Patrol As Stakeholders Watch For Details
FDA’s Pharmacoepidemiology Studies Could Be Funded Through Reagan-Udall
FDA Safety Monitoring Could Rely On Data Links, Menactra Model – McClellan
FDA Safety Monitoring Could Rely On Data Links, Menactra Model – McClellan
Advertisement
UsernamePublicRestriction

Register

PS049783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel